GPCR: Structure Therapeutics Inc - American Depositary Shares

GPCR新闻

• 13:34 Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
• 12:56 LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?
• 11:19 GLP-1 Sales Forecast Jumps To $150 Billion By 2030
• 14:49 LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
• 14:14 Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
• 14:34 LLY Reports Third Phase III Win for Next-Generation Obesity Drug
• 15:35 Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
• 14:20 Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
• 15:47 Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
• 15:23 NVO Rallies 21% in a Month: How Should Investors Play the Stock?
• 16:05 LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
• 17:10 Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
• 16:06 Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
• 18:40 Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market - TipRanks.com
• 16:53 LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study
• 13:33 LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill
• 13:04 How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?
• 14:20 Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
• 20:14 Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy
• 16:55 How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval
• 13:50 LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?
• 12:15 Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster (GPCR)
• 14:53 NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
• 11:17 Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial